基因治疗恢复多巴胺转运体表达并改善婴儿型帕金森病模型病理
研究利用患者来源iPSC构建多巴胺转运体缺陷综合征(DTDS)中脑多巴胺能神经元模型,发现DAT活性受损、TNFα介导炎症及多巴胺毒性;慢病毒转染野生型SLC6A3可恢复DAT活性并防止神经退行性变。在DTDS敲除小鼠中,新生期脑室内注射AAV载体表达人DAT改善运动表型、寿命和神经元存活,但高剂量有脱靶神经毒性;成年小鼠中脑立体定向AAV2.SLC6A3治疗可挽救运动表型和神经退行性变。
要点
- 慢病毒转染野生型SLC6A3可恢复所有患者iPSC来源mDA神经元的DAT活性并防止神经退行性变。
- 新生期脑室内AAV递送人SLC6A3改善DTDS敲除小鼠运动表型、寿命及黑质纹状体神经元存活。
- 高剂量AAV有脱靶神经毒性,中脑立体定向AAV2.SLC6A3治疗可避免并挽救成年小鼠表型。
核心结论
- 靶向中脑的AAV基因治疗可能对DTDS患者有效。
研究设计与样本
- 利用患者来源iPSC构建DTDS中脑多巴胺能神经元模型。
- 使用DTDS敲除小鼠模型,新生期脑室内注射AAV或成年期中脑立体定向注射AAV2.SLC6A3。
主要发现
- 患者iPSC来源mDA神经元显示DAT活性受损、TNFα介导炎症相关的凋亡性神经退行性变及多巴胺毒性。
- 药理学伴侣pifithrin-μ部分恢复DAT活性具有突变特异性。
- 慢病毒转染野生型人SLC6A3 cDNA恢复所有患者mDA细胞系DAT活性并防止神经退行性变。
- 新生期脑室内AAV递送人SLC6A3改善敲除小鼠运动表型、寿命及黑质和纹状体神经元存活,高剂量出现脱靶神经毒性。
- 成年敲除小鼠中脑立体定向AAV2.SLC6A3治疗挽救运动表型和神经退行性变。
临床怎么用
- 针对DTDS的中脑靶向AAV基因治疗策略值得向临床转化推进。
局限性
- 新生期脑室内高剂量AAV递送观察到脱靶神经毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Most inherited neurodegenerative disorders are incurable, and often only palliative treatment is available. Precision medicine has great potential to address this unmet clinical need. We explored this paradigm in dopamine transporter deficiency syndrome (DTDS), caused by biallelic loss-of-function mutations in SLC6A3, encoding the dopamine transporter (DAT). Patients present with early infantile hyperkinesia, severe progressive childhood parkinsonism, and raised cerebrospinal fluid dopamine metabolites. The absence of effective treatments and relentless disease course frequently leads to death in childhood. Using patient-derived induced pluripotent stem cells (iPSCs), we generated a midbrain dopaminergic (mDA) neuron model of DTDS that exhibited marked impairment of DAT activity, apoptotic neurodegeneration associated with TNFα-mediated inflammation, and dopamine toxicity. Partial restoration of DAT activity by the pharmacochaperone pifithrin-μ was mutation-specific. In contrast, lentiviral gene transfer of wild-type human SLC6A3 complementary DNA restored DAT activity and prevented neurodegeneration in all patient-derived mDA lines. To progress toward clinical translation, we used the knockout mouse model of DTDS that recapitulates human disease, exhibiting parkinsonism features, including tremor, bradykinesia, and premature death. Neonatal intracerebroventricular injection of human SLC6A3 using an adeno-associated virus (AAV) vector provided neuronal expression of human DAT, which ameliorated motor phenotype, life span, and neuronal survival in the substantia nigra and striatum, although off-target neurotoxic effects were seen at higher dosage. These were avoided with stereotactic delivery of AAV2.SLC6A3 gene therapy targeted to the midbrain of adult knockout mice, which rescued both motor phenotype and neurodegeneration, suggesting that targeted AAV gene therapy might be effective for patients with DTDS.
引用
- Ng J, Barral S, De La Fuente Barrigon C, et al. Gene therapy restores dopamine transporter expression and ameliorates pathology in iPSC and mouse models of infantile parkinsonism. Sci Transl Med. 2021. PMID: 34011628. doi:10.1126/scitranslmed.aaw1564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。